CN110201150A - 一种增加人体细胞活性抗hpv的药物 - Google Patents
一种增加人体细胞活性抗hpv的药物 Download PDFInfo
- Publication number
- CN110201150A CN110201150A CN201910630800.4A CN201910630800A CN110201150A CN 110201150 A CN110201150 A CN 110201150A CN 201910630800 A CN201910630800 A CN 201910630800A CN 110201150 A CN110201150 A CN 110201150A
- Authority
- CN
- China
- Prior art keywords
- human body
- hpv
- dosage
- cell activity
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 25
- 229940079593 drug Drugs 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 36
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 36
- 235000008434 ginseng Nutrition 0.000 claims abstract description 36
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 20
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 20
- 235000014676 Phragmites communis Nutrition 0.000 claims abstract description 20
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 19
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 19
- 108010010803 Gelatin Proteins 0.000 claims abstract description 18
- 241001248610 Ophiocordyceps sinensis Species 0.000 claims abstract description 18
- 229920000159 gelatin Polymers 0.000 claims abstract description 18
- 239000008273 gelatin Substances 0.000 claims abstract description 18
- 235000019322 gelatine Nutrition 0.000 claims abstract description 18
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 18
- 239000007788 liquid Substances 0.000 claims abstract description 17
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims abstract description 15
- 244000291414 Vaccinium oxycoccus Species 0.000 claims abstract description 15
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims abstract description 15
- 235000004634 cranberry Nutrition 0.000 claims abstract description 15
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 15
- 239000011707 mineral Substances 0.000 claims abstract description 15
- 241001265053 Dolichandra unguis-cati Species 0.000 claims abstract description 14
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 claims abstract description 11
- 241000208680 Hamamelis mollis Species 0.000 claims abstract description 11
- 241000212322 Levisticum officinale Species 0.000 claims abstract description 11
- 239000001645 levisticum officinale Substances 0.000 claims abstract description 11
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 claims abstract description 11
- 229940052490 naringin Drugs 0.000 claims abstract description 11
- 229930019673 naringin Natural products 0.000 claims abstract description 11
- 229940118846 witch hazel Drugs 0.000 claims abstract description 11
- 241001116389 Aloe Species 0.000 claims abstract description 10
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 10
- 244000081757 Phalaris arundinacea Species 0.000 claims abstract description 9
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 6
- 240000001432 Calendula officinalis Species 0.000 claims abstract description 6
- 235000005881 Calendula officinalis Nutrition 0.000 claims abstract description 6
- 244000143590 Salvia chinensis Species 0.000 claims abstract description 6
- 235000007154 Salvia chinensis Nutrition 0.000 claims abstract description 6
- 235000005794 Salvia japonica Nutrition 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract 7
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 22
- 229920002674 hyaluronan Polymers 0.000 claims description 18
- 229960003160 hyaluronic acid Drugs 0.000 claims description 17
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 16
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 16
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 16
- 235000008696 isoflavones Nutrition 0.000 claims description 16
- 102000016942 Elastin Human genes 0.000 claims description 15
- 108010014258 Elastin Proteins 0.000 claims description 15
- 229920002549 elastin Polymers 0.000 claims description 15
- 239000011718 vitamin C Substances 0.000 claims description 11
- 240000000249 Morus alba Species 0.000 claims description 5
- 235000008708 Morus alba Nutrition 0.000 claims description 5
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Substances 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 229910052711 selenium Inorganic materials 0.000 claims description 3
- 239000011669 selenium Substances 0.000 claims description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 20
- 210000004027 cell Anatomy 0.000 abstract description 19
- 239000000126 substance Substances 0.000 abstract description 14
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 abstract description 11
- 229940011871 estrogen Drugs 0.000 abstract description 10
- 239000000262 estrogen Substances 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract description 8
- 230000012010 growth Effects 0.000 abstract description 5
- 206010059313 Anogenital warts Diseases 0.000 abstract description 4
- 208000000907 Condylomata Acuminata Diseases 0.000 abstract description 4
- 208000019065 cervical carcinoma Diseases 0.000 abstract description 4
- 210000004392 genitalia Anatomy 0.000 abstract description 4
- 210000001672 ovary Anatomy 0.000 abstract description 4
- 230000009467 reduction Effects 0.000 abstract description 4
- 230000001771 impaired effect Effects 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 206010027476 Metastases Diseases 0.000 abstract description 2
- 230000012292 cell migration Effects 0.000 abstract description 2
- 230000009401 metastasis Effects 0.000 abstract description 2
- 230000003248 secreting effect Effects 0.000 abstract description 2
- 240000004371 Panax ginseng Species 0.000 description 29
- 208000015181 infectious disease Diseases 0.000 description 9
- 239000011782 vitamin Substances 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000037303 wrinkles Effects 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 230000032683 aging Effects 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 201000010153 skin papilloma Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000001215 vagina Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108010059616 Activins Proteins 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000000488 activin Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- KQLDDLUWUFBQHP-UHFFFAOYSA-N Cordycepin Natural products C1=NC=2C(N)=NC=NC=2N1C1OCC(CO)C1O KQLDDLUWUFBQHP-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000004449 DNA Virus Infections Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000701806 Human papillomavirus Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000082490 Proboscidea louisianica Species 0.000 description 1
- 235000015926 Proboscidea louisianica ssp. fragrans Nutrition 0.000 description 1
- 235000015925 Proboscidea louisianica subsp. louisianica Nutrition 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- OFEZSBMBBKLLBJ-BAJZRUMYSA-N cordycepin Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)C[C@H]1O OFEZSBMBBKLLBJ-BAJZRUMYSA-N 0.000 description 1
- OFEZSBMBBKLLBJ-UHFFFAOYSA-N cordycepine Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)CC1O OFEZSBMBBKLLBJ-UHFFFAOYSA-N 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 231100000284 endotoxic Toxicity 0.000 description 1
- 230000002346 endotoxic effect Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/066—Clavicipitaceae
- A61K36/068—Cordyceps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于医药技术领域，提供一种增加人体细胞活性抗HPV的药物，包含荻苇草、液体矿物质、虫草、灵芝菌、红人参、阿胶、西红花、人参、有机蔓越莓、猫爪藤、金缕梅、圆叶当归根、柑橘苷、芦荟、鼠尾草、有机银花叶、金盏花和黑桑；荻苇草促进女性荷尔蒙分泌，增加女性荷尔蒙分泌量，改善女性卵巢功能下降，液体矿物质中的营养物质容易被人体吸收激发细胞活性，净化肿瘤细胞，虫草抑制肿瘤生长和转移，红人参促进受损粘膜修复，已解决高危型的HPV感染和外生殖器的低危型HPV感染造成的生殖器疣和宫颈癌损害人体肌肤具备传染性，威胁患者及其家属人生安全的问题。
Description
技术领域
本发明属于医药技术领域，具体涉及一种增加人体细胞活性抗HPV的药物。
背景技术
HPV病毒是人类乳头瘤病毒的缩写，是一种乳多空病毒科的乳头瘤空泡病毒A属，是球形DNA病毒感染引起的一种性传播疾病。
皮肤型的HPV人群感染率十分普遍，如寻常疣、趾疣和扁平疣等，高危型的HPV感染和外生殖器的低危型HPV感染造成的生殖器疣和宫颈癌损害人体皮肤具备传染性，威胁患者及其家属人生安全。
发明内容
本发明在于提供一种增加人体细胞活性抗HPV的药物，以解决高危型的HPV感染和外生殖器的低危型HPV感染造成的生殖器疣和宫颈癌损害人体肌肤，威胁患者及其家属人生安全的问题。
本发明是这样实现的，本发明提供一种增加人体细胞活性抗HPV的药物，包含15g-30g荻苇草、5g-15g液体矿物质、10g-20g虫草、20g-30g灵芝菌、5g-10g红人参、2g-6g阿胶、5g-25g西红花、5g-10g人参、10g-20g有机蔓越莓、5g-10g猫爪藤、5g-10g金缕梅、5g-10g圆叶当归根、5g-10g柑橘苷、5g-15g芦荟、5g-15g鼠尾草、5g-15g有机银花叶、5g-15g金盏花和5g-15g黑桑。
优选的，还包括15g-20g左旋维生素C，其中，所述左旋维生素C、虫草和灵芝菌的含量之和不超过70g。
优选的，还包括5g-15g乳酸杆菌，其中,所述乳酸杆菌的用量小于红人参、阿胶和西红花的用量之和。
优选的，还包括5g-10g透明质酸，其中，所述透明质酸、人参、有机蔓越莓和猫爪藤的用量之和在25g-45g之间。
优选的，还包括2g-8g弹力蛋白,其中，所述弹力蛋白、金缕梅和圆叶当归根的用量之和不超过20g。
优选的，还包括2g-5g异黄酮，其中，所述异黄酮、柑橘苷和芦荟的用量之和不超过25g。
优选的，所述液体矿物质中包含碘元素、锌元素、硒元素、铜元素、钼元素、铬元素、钴元素和铁元素。
与现有的方法相比，本发明的有益效果是：荻苇草促进女性荷尔蒙分泌，通过增加女性荷尔蒙分泌量，改善女性卵巢功能下降，荷尔蒙缺少所带来得各种亚健康病状，液体矿物质中的营养物质容易被人体吸收激发细胞活性，矿物质与人体内的肿瘤细胞产生离子反应，净化肿瘤细胞，并进行深层排毒，通过虫草增强人体红细胞粘附肿瘤细胞的能力，抑制肿瘤生长和转移，通过红人参促进受损粘膜修复，改善肌肤质量，已解决高危型的HPV感染和外生殖器的低危型HPV感染造成的生殖器疣和宫颈癌损害人体肌肤具备传染性，威胁患者及其家属人生安全的问题。
具体实施方式
下面将对发明实施例中的技术方法进行清楚、完整地描述，显然，所描述的实施例仅仅是发明一部分实施例，而不是全部的实施例。基于发明中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例，都属于发明保护的范围。
实施例1
本发明提供一种增加人体细胞活性抗HPV的药物，包含15g-30g荻苇草、5g-15g液体矿物质、10g-20g虫草、20g-30g灵芝菌、5g-10g红人参、2g-6g阿胶、5g-25g西红花、5g-10g人参、10g-20g有机蔓越莓、5g-10g猫爪藤、5g-10g金缕梅、5g-10g圆叶当归根、5g-10g柑橘苷、5g-15g芦荟、5g-15g鼠尾草、5g-15g有机银花叶、5g-15g金盏花和5g-15g黑桑。
在本实施方式中，通过荻苇草促进女性荷尔蒙分泌，从根源上改善女性肌肤质量，调节女性卵巢功能下降，荷尔蒙缺少所带来的各类亚健康病状，通过液体矿物质激活人体细胞活性，同时液体矿物质在人体内与肿瘤细胞产生离子反应，净化肿瘤细胞及被肿瘤细胞污染的正常细胞，并对细胞进行深层排毒，通过虫草中的虫草素增强红细胞粘附肿瘤细胞的能力，感染初期，通过红细胞对肿瘤细胞进行灭活，感染后期，通过红细胞对肿瘤细胞产生抑制，通过灵芝菌提高人体自身免疫力，抑制肿瘤细胞的繁殖，通过西红花改善人体血液循环的血液供给能力，改善血液微循环，补充人体内每个细胞的血液、水分和营养，加强人体内红细胞的活性的同时，调节色素在肌肤表面的沉淀，减少皱纹和黑色素，使肌肤更加细腻光泽有弹性。
在本实施方式中，通过人参调节人体的中枢神经系统，加速人体内新陈代谢，通过加速人体新陈代谢循环将人体内将人体内的毒素排出，通过有机蔓越莓抑制多种致病细菌的生长和繁殖，预防和控制女性生殖系统感染以及抑制幽门螺旋杆菌感染，维持女性生殖系统正常PH值。
进一步的，还包括15g-20g左旋维生素C，其中，所述左旋维生素C、虫草和灵芝菌的含量之和不超过70g。
在本实施方式中，植物中的D-葡萄糖可经由转化酵素变为维生素C,通过左旋维生素C抑制酪胺酸酶及还原黑色素，并淡化以形成的斑点，抑制黑色素形成，促进人体胶原蛋白合成减少细纹，人体内若缺乏左旋维生素C容易造成皮肤松弛老化，产生皱纹，愈老化的皮肤所含左旋维生素C的含量愈少，故需随时补充，皮肤受到外界环境影响时，会形成游离自由基，自由基会破坏正常组织内的胶原蛋白、弹力素，造成老化、产生细纹和皱纹，左旋维生素C能有效中和自由基，改善肌肤纹路，还原受损肌肤，让肌肤紧实有弹性，同时增加人体肌肤的弹性。
进一步的，还包括5g-15g乳酸杆菌，其中,所述乳酸杆菌的用量小于红人参、阿胶和西红花的用量之和。
在本实施方式中，乳酸杆菌阻止病原菌对肠道的入侵和定植，抑制病原菌，抗感染，维持人体内的微生态平衡，预防和抑制肿瘤的发生，增强人体机体免疫力，促进消化，合成氨基酸和维生素，降低胆固醇，抑制内毒素的生产，延缓衰老和抗辐射等功效，当人体肠道内的乳酸杆菌数量减少或丢失，出现菌群失调，就可导致某种疾病的发生，当肠道内的乳酸杆菌数量增加，区系得到平衡，就可以促进人体机体健康和治疗疾病。
进一步的，还包括5g-10g透明质酸，其中，所述透明质酸、人参、有机蔓越莓和猫爪藤的用量之和在25g-45g之间。
在本实施方式中，透明质酸是构成人体细胞间隙、眼玻璃体、关节滑液等结缔组织的主要成分，在体内发挥保水、维持细胞内外空间、调节渗透压、润滑、促进细胞修复的重要生理功能，透明质酸分子中含有大量的羟基和羧基，在水溶液中形成分子内和分子间的氢键，这使其具备强大的保水作用，可结合自身400倍以上的水，透明质酸作为细胞间基质的主要成分，直接参与细胞内外电解质交流的调控，发挥物理和分子信息的过滤器作用。大分子透明质酸对细胞移动、增殖、分化及吞噬功能有抑制作用，小分子透明质酸则有促进作用。
进一步的，还包括2g-8g弹力蛋白,其中，所述弹力蛋白、金缕梅和圆叶当归根的用量之和不超过20g。
在本实施方式中，弹力蛋白为一种水不溶性、高交叉度的水解蛋白，弹性蛋白分子中非极性氨基酸占95%，甘氨酸含量接近总量的三分之一，脯氨酸占10%，羟脯氨酸占1%，弹力蛋白抗酸、碱水解，100℃以下不溶于多种氢键断裂溶剂，而发生溶胀，不溶于酚类溶剂。除断裂肽键剂外，它不溶于任何溶剂。弹性蛋白是一种在水存在下具有橡胶延展性和低弹性模量的聚合物，通过弹性蛋白使弹性纤维与胶原纤维共存，赋予人体结缔组织以弹性和扩张能力。
进一步的，还包括2g-5g异黄酮，其中，所述异黄酮、柑橘苷和芦荟的用量之和不超过25g。
在本实施方式中，异黄酮具备双向调节作用，异黄酮在化学上作为结构类似物与雌激素活性有关，显示抑制和协同的双向调节功效，当人体内雌激素水平偏低时，异黄酮占据雌激素受体，发挥弱雌激素效应，表现出提高雌激素水平的作用，当人体内雌激素水平过高时，异黄酮占据受体位置，选择性的与雌激素受体结合且性质温和与脑、前列腺、膀胱、心血管和骨组织等受体的亲和力强，对子宫、卵巢、乳腺等的亲和力弱，同时异黄酮活性只有雌性激素的千分之一和十万分之一，因而避免了补充雌激素可能诱发癌症的风险。
进一步的，所述液体矿物质中包含碘元素、锌元素、硒元素、铜元素、钼元素、铬元素、钴元素和铁元素。
在本实施方式中，液体矿物质中包含钙、镁、钾、钠、磷、硫和氯等微量元素，微量元素在人体含量中含量极少，但具有强大的生物作用，直接参与酶、激素和核算的代谢过程，其生理功能主要表现为协助输送宏量元素，微量元素作为酶的组成成分或激活剂，在激素和维生素中起独特作用，影响核酸代谢等，通过液体矿物质中的微量元素激活人体内的细胞活性，同时液体矿物质中的微量元素与人体内的肿瘤细胞产生离子反应，改善人体细胞内环境，净化肿瘤细胞及被肿瘤细胞污染的正常细胞，并对细胞进行深层排毒。
在本实施方式中，左旋维生素、虫草和灵芝菌的用量之和不超过70g，灵芝菌的用量相比较左旋维生素和虫草的用量较多，灵芝菌具备抗疲劳、抗衰老、美容养颜、提高人体免疫机能，防止肿瘤细胞扩散传染，乳酸杆菌的用量小于红人参、阿胶和西红花的用量之和，红人参、阿胶和西红花的用量之和大于乳酸杆菌的用量，减少乳酸杆菌对红人参、阿胶和西红花的作用产生影响，在乳酸杆菌维持阴道自净的同时提高其抗感染力，减少HPV肿瘤细胞扩散繁殖，透明质酸、有机蔓越莓、人参和猫爪藤用量之和在25g-45g之间，透明质酸、有机蔓越莓、人参和猫爪藤增强人体机体免疫力，同时防止肿瘤细胞扩散对人体皮肤产生影响，通过弹力蛋白、金缕梅和圆叶当归根用量之和不超过20g,调节人体细纹，减少皱纹，通过异黄酮、柑橘苷和芦荟的用量之和不超过25g，改善女性经期不稳定，预防改善由于骨质疏松导致的癌症。
实施例2
如上述实施例1所述，在本实施例中，
进一步的，包含15g荻苇草、5g液体矿物质、10g虫草、20g灵芝菌、5g红人参、2g阿胶、5g西红花、5g人参、10g有机蔓越莓、5g猫爪藤、5g金缕梅、5g圆叶当归根、5g柑橘苷、5g芦荟、5g鼠尾草、5g有机银花叶、5g金盏花、5g黑桑、15g左旋维生素C、5g乳酸杆菌、5g透明质酸、2g弹力蛋白和2g异黄酮。
在本实施方式中，15g左旋维生素、10g虫草和20g灵芝菌的用量之和不超过70g，20g灵芝菌的用量相比较15g左旋维生素和10g虫草的用量较多，灵芝菌具备抗疲劳、抗衰老、美容养颜、提高人体免疫机能，防止肿瘤细胞扩散传染，5g乳酸杆菌的用量小于5g红人参、2g阿胶和5g西红花的用量之和，通过设置5g红人参、2g阿胶和5g西红花的用量之和大于5g乳酸杆菌的用量，减少乳酸杆菌对红人参、阿胶和西红花产生影响，在乳酸杆菌维持阴道自净的同时提高其抗感染力，减少HPV肿瘤细胞扩散繁殖，5g透明质酸、10g有机蔓越莓、5g人参和5g猫爪藤用量之和在25g-45g之间，透明质酸、有机蔓越莓、人参和猫爪藤增强人体机体免疫力，同时防止肿瘤细胞扩散对人体皮肤产生影响，通过2g弹力蛋白、5g金缕梅和5g圆叶当归根用量之和不超过20g,调节人体细纹，减少皱纹，通过2g异黄酮、5g柑橘苷和5g芦荟的用量之和不超过25g，改善女性经期不稳定，预防改善由于骨质疏松导致的癌症。
实施例3
如上述实施例1所述，在本实施例中，
进一步的，包含30g荻苇草、15液体矿物质、20g虫草、30g灵芝菌、10g红人参、6g阿胶、25西红花、10g人参、20g有机蔓越莓、5g猫爪藤、10g金缕梅、5g圆叶当归根、5g柑橘苷、15g芦荟、15g鼠尾草、15g有机银花叶、15g金盏花、15g黑桑、20g左旋维生素C、15g乳酸杆菌、10g透明质酸、5g弹力蛋白和5g异黄酮。
在本实施方式中，20g左旋维生素、20g虫草和30g灵芝菌的用量之和不超过70g，30g灵芝菌的用量相比较20g左旋维生素和20g虫草的用量较多，灵芝菌具备抗疲劳、抗衰老、美容养颜、提高人体免疫机能，防止肿瘤细胞扩散传染，15g乳酸杆菌的用量小于10g红人参、6g阿胶和25g西红花的用量之和，通过设置5g红人参、2g阿胶和5g西红花的用量之和大于5g乳酸杆菌的用量，减少乳酸杆菌对红人参、阿胶和西红花产生影响，在乳酸杆菌维持阴道自净的同时提高其抗感染力，减少HPV肿瘤细胞扩散繁殖，同时25g西红花的大量使用对人体内的血液进行养护调节，促进血液循环的血氧供给能力，改善血液体内微循环、补充人体细胞的血氧、水分和营养，调节肌肤色素，减少人体皱纹，10g透明质酸、20g有机蔓越莓、10g人参和5g猫爪藤用量之和在25g-45g之间，透明质酸、有机蔓越莓、人参和猫爪藤增强人体机体免疫力，同时防止肿瘤细胞扩散对人体皮肤产生影响，通过5g弹力蛋白、10g金缕梅和5g圆叶当归根用量之和不超过20g,调节人体细纹，减少皱纹，通过5g异黄酮、5g柑橘苷和15g芦荟的用量之和不超过25g，改善女性经期不稳定，预防改善由于骨质疏松导致的癌症。
可以理解在不脱离发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变型，发明的范围由所附权利要求及其等同物限定。
Claims (7)
1.一种增加人体细胞活性抗HPV的药物，其特征在于：包含15g-30g荻苇草、5g-15g液体矿物质、10g-20g虫草、20g-30g灵芝菌、5g-10g红人参、2g-6g阿胶、5g-25g西红花、5g-10g人参、10g-20g有机蔓越莓、5g-10g猫爪藤、5g-10g金缕梅、5g-10g圆叶当归根、5g-10g柑橘苷、5g-15g芦荟、5g-15g鼠尾草、5g-15g有机银花叶、5g-15g金盏花和5g-15g黑桑。
2.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：还包括15g-20g左旋维生素C，其中，所述左旋维生素C、虫草和灵芝菌的含量之和不超过70g。
3.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：还包括5g-15g乳酸杆菌，其中,所述乳酸杆菌的用量小于红人参、阿胶和西红花的用量之和。
4.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：还包括5g-10g透明质酸，其中，所述透明质酸、人参、有机蔓越莓和猫爪藤的用量之和在25g-45g之间。
5.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：还包括2g-8g弹力蛋白,其中，所述弹力蛋白、金缕梅和圆叶当归根的用量之和不超过20g。
6.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：还包括2g-5g异黄酮，其中，所述异黄酮、柑橘苷和芦荟的用量之和不超过25g。
7.根据权利要求1所述的一种增加人体细胞活性抗HPV的药物，其特征在于：所述液体矿物质中包含碘元素、锌元素、硒元素、铜元素、钼元素、铬元素、钴元素和铁元素。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910630800.4A CN110201150A (zh) | 2019-07-12 | 2019-07-12 | 一种增加人体细胞活性抗hpv的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910630800.4A CN110201150A (zh) | 2019-07-12 | 2019-07-12 | 一种增加人体细胞活性抗hpv的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110201150A true CN110201150A (zh) | 2019-09-06 |
Family
ID=67797319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910630800.4A Pending CN110201150A (zh) | 2019-07-12 | 2019-07-12 | 一种增加人体细胞活性抗hpv的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110201150A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115486538A (zh) * | 2022-09-14 | 2022-12-20 | 广州通泽医疗科技有限公司 | 一种具有保护女性生殖系统功效的组合物及其制备方法和应用 |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1960743A (zh) * | 2003-04-16 | 2007-05-09 | 薰衣草作物项目有限公司 | 草药组合物 |
| CN101032607A (zh) * | 2007-03-31 | 2007-09-12 | 王成斌 | 治疗尖锐湿疣的药物 |
| CN103041283A (zh) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | 一种外用治疗宫颈hpv感染的中药组合物及其制备方法 |
| CN103341106A (zh) * | 2013-07-29 | 2013-10-09 | 北京百睿宏嘉生物科技有限公司 | 一种冬虫夏草抗菌消炎凝胶及其制备方法 |
| CN104042654A (zh) * | 2013-03-12 | 2014-09-17 | 江中药业股份有限公司 | 一种组合物在制备抗hpv保健品或药品或产品中的应用 |
| CN104839650A (zh) * | 2015-04-08 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 宫颈癌医学配方食品 |
| CN107184911A (zh) * | 2017-06-19 | 2017-09-22 | 太原谷歌医药科技有限公司 | 一种用于预防宫颈癌和治疗乳头瘤病毒（hpv）感染及阴道炎症的产品及制备方法 |
| CN108186718A (zh) * | 2018-03-13 | 2018-06-22 | 余晓晴 | 一种预防及抑制hpv病毒的妇科喷剂 |
| CN108542954A (zh) * | 2018-05-22 | 2018-09-18 | 湖南千金养生坊健康品股份有限公司 | 一种抑菌抗病毒的中药凝胶组合物 |
| CN108853287A (zh) * | 2018-08-07 | 2018-11-23 | 吉林省正肽生物科技有限公司 | 一种抗人乳头瘤病毒及抗妇科炎症的药物组合物、凝胶制剂及应用 |
| CN108976269A (zh) * | 2018-01-24 | 2018-12-11 | 李立 | 一种从柚子鲜幼果中快速制备高纯柚皮苷的方法 |
| CN109106806A (zh) * | 2018-06-20 | 2019-01-01 | 广州宏韵医药科技股份有限公司 | 一种女性私密护理洗液及其制备方法 |
| CN109674903A (zh) * | 2019-01-29 | 2019-04-26 | 罗梦芝 | 一种子宫肌瘤、子宫腺肌症、宫颈息肉、hpv的治疗药物 |
-
2019
- 2019-07-12 CN CN201910630800.4A patent/CN110201150A/zh active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1960743A (zh) * | 2003-04-16 | 2007-05-09 | 薰衣草作物项目有限公司 | 草药组合物 |
| CN101032607A (zh) * | 2007-03-31 | 2007-09-12 | 王成斌 | 治疗尖锐湿疣的药物 |
| CN103041283A (zh) * | 2011-10-12 | 2013-04-17 | 薛晓鸥 | 一种外用治疗宫颈hpv感染的中药组合物及其制备方法 |
| CN104042654A (zh) * | 2013-03-12 | 2014-09-17 | 江中药业股份有限公司 | 一种组合物在制备抗hpv保健品或药品或产品中的应用 |
| CN103341106A (zh) * | 2013-07-29 | 2013-10-09 | 北京百睿宏嘉生物科技有限公司 | 一种冬虫夏草抗菌消炎凝胶及其制备方法 |
| CN104839650A (zh) * | 2015-04-08 | 2015-08-19 | 劲膳美生物科技股份有限公司 | 宫颈癌医学配方食品 |
| CN107184911A (zh) * | 2017-06-19 | 2017-09-22 | 太原谷歌医药科技有限公司 | 一种用于预防宫颈癌和治疗乳头瘤病毒（hpv）感染及阴道炎症的产品及制备方法 |
| CN108976269A (zh) * | 2018-01-24 | 2018-12-11 | 李立 | 一种从柚子鲜幼果中快速制备高纯柚皮苷的方法 |
| CN108186718A (zh) * | 2018-03-13 | 2018-06-22 | 余晓晴 | 一种预防及抑制hpv病毒的妇科喷剂 |
| CN108542954A (zh) * | 2018-05-22 | 2018-09-18 | 湖南千金养生坊健康品股份有限公司 | 一种抑菌抗病毒的中药凝胶组合物 |
| CN109106806A (zh) * | 2018-06-20 | 2019-01-01 | 广州宏韵医药科技股份有限公司 | 一种女性私密护理洗液及其制备方法 |
| CN108853287A (zh) * | 2018-08-07 | 2018-11-23 | 吉林省正肽生物科技有限公司 | 一种抗人乳头瘤病毒及抗妇科炎症的药物组合物、凝胶制剂及应用 |
| CN109674903A (zh) * | 2019-01-29 | 2019-04-26 | 罗梦芝 | 一种子宫肌瘤、子宫腺肌症、宫颈息肉、hpv的治疗药物 |
Non-Patent Citations (5)
| Title |
|---|
| 孔令义主编: "《天然药物化学》", 31 August 2015 * |
| 张正付等: "鼠尾草属植物化学成分及活性研究新进展" * |
| 张雷红等主编: "《天然药物化学 第3版》", 31 January 2017 * |
| 王磊: "黑桑化学成分及生物活性研究" * |
| 阎冰冰等: "乳酸杆菌对阻断高危型HPV持续性感染作用的前瞻性研究" * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115486538A (zh) * | 2022-09-14 | 2022-12-20 | 广州通泽医疗科技有限公司 | 一种具有保护女性生殖系统功效的组合物及其制备方法和应用 |
| CN115486538B (zh) * | 2022-09-14 | 2023-09-15 | 广州通泽医疗科技有限公司 | 一种具有保护女性生殖系统功效的组合物及其制备方法和应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111574618B (zh) | 美白复合蛋白肽酶解液的制备方法、美白复合蛋白肽饮品及其制备方法 | |
| CN107823095A (zh) | 一种活性肽面膜 | |
| CN208279353U (zh) | 一种雾状小分子富氢水制备装置 | |
| CN102085172B (zh) | 一种以美洲荻尾草提取物为主要组分的护肤化妆品及其制备方法 | |
| WO2018000665A1 (zh) | 一种能让乳房丰满紧致和预防乳腺疾病的精华液 | |
| CN109172491A (zh) | 一种具有抗衰老和活血化瘀功能的霜剂及其制备方法 | |
| CN110151975A (zh) | 一种抗辐射蓝光改善视力的清润液及其制备方法 | |
| CN105639560A (zh) | 一种用于安神助眠的生物酶解法破壁灵芝孢子粉蜂蜜及其制作工艺 | |
| CN110916200A (zh) | 一种降尿酸组合物及其制备方法 | |
| CN110201150A (zh) | 一种增加人体细胞活性抗hpv的药物 | |
| CN105902477B (zh) | 综合改善眼部活力的生物制剂及其制备方法 | |
| CN109260120A (zh) | 一种莹肌如瑜散发酵原浆化妆品及其制备方法与应用 | |
| CN106333977A (zh) | 一种治疗骨质疏松性骨折和/或骨关节炎的天然药物组合物及其用途 | |
| KR20190000816A (ko) | 생분해성 고분자와 황토가 결합되어 탄력성이 증진된 기능성 마스크팩 및 그의 제조방법 | |
| CN107712517A (zh) | 一种竹荪小分子肽复配营养肽水饮料及其制备方法 | |
| CN108056964A (zh) | 一种美胸精油组合物 | |
| CN107365817A (zh) | 大豆蛋白水解物及其制备方法和应用 | |
| CN107823079A (zh) | 一种海参egf组合物护肤化妆品及其制备方法 | |
| CN109172492A (zh) | 一种速愈霜及其制备方法 | |
| CN104666234A (zh) | 一种含螺旋藻的化妆品 | |
| CN116212007B (zh) | 一种治疗中期骨折的接骨柔筋中药组合物及其制备方法 | |
| KR20210085684A (ko) | 미백 및 주름개선을 위한 피부미용 건강식품 조성물 | |
| CN104587456A (zh) | 一种增加骨密度的保健品的制作工艺 | |
| CN1061892C (zh) | 治疗肿瘤口服液及其制备方法 | |
| CN107736528A (zh) | 一种黑芝麻小分子肽复配营养肽水饮料及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190906 |